Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana

Ontlametse T. Bareng,Sikhulile Moyo,Mbatshi Mudanga,Kagiso Sebina,Catherine K. Koofhethile,Wonderful T. Choga,Natasha O. Moraka,Dorcas Maruapula,Irene Gobe,Modisa S. Motswaledi,Rosemary Musonda,Bornapate Nkomo,Dinah Ramaabya,Tony Chebani,Penny Makuruetsa,Joseph Makhema,Roger Shapiro,Shahin Lockman,Simani Gaseitsiwe

DOI: https://doi.org/10.3390/v16050720

2024-05-02

Viruses

Abstract:We evaluated subsequent virologic outcomes in individuals experiencing low-level virem ia (LLV) on dolutegravir (DTG)-based first-line antiretroviral therapy (ART) in Botswana. We used a national dataset from 50,742 adults who initiated on DTG-based first-line ART from June 2016–December 2022. Individuals with at least two viral load (VL) measurements post three months on DTG-based first-line ART were evaluated for first and subsequent episodes of LLV (VL:51–999 copies/mL). LLV was sub-categorized as low-LLV (51–200 copies/mL), medium-LLV (201–400 copies/mL) and high-LLV (401–999 copies/mL). The study outcome was virologic failure (VF) (VL ≥ 1000 copies/mL): virologic non-suppression defined as single-VF and confirmed-VF defined as two-consecutive VF measurements after an initial VL 6–12 (2.8%) and >12–24 (3.9%) (p-value 400 copies/mL and persistent-LLV had a stronger association with VF. Frequent VL testing and adherence support are warranted for individuals with VL > 50 copies/mL.

virology